The Other Person in the Waiting Room: caregivers and the CRS/HIPEC decision
Amanda Moore Avatar

Short answer: Most people with appendix cancer who make the CRS/HIPEC decision don’t regret it. Caregivers carry a heavy load, though, and their regret is higher when their loved one dies. That comes from three studies: a 2024 patient study and a 2025 caregiver study from the University of New Mexico, and Yale’s DECISIVE study, published in Annals of Surgical Oncology on September 23, 2026.

Why I’m writing about caregivers

I’m a caregiver. My husband David was diagnosed with goblet cell adenocarcinoma in 2024. In the Appendicure community, whether to have CRS/HIPEC comes up constantly, and the caregiver is usually right in the middle of it. They sit through the consults, write down what the surgeon said, and handle the recovery at home. Until recently, very few researchers had asked caregivers how the CRS/HIPEC decision went for them.

What patients said about regret after CRS/HIPEC

In 2024, Dr. Alissa Greenbaum’s team at the University of New Mexico published a survey of 122 people with appendix cancer who’d had CRS/HIPEC. It was run with ACPMP. The team used the Decision Regret Scale, a standard questionnaire researchers use to measure how people feel about a medical decision after the fact. Eighteen people, about 15 out of every 100, scored high enough to count as having regret. Most of the people in the study had low-grade tumors.

Regret was more common in people who stayed in the hospital more than 30 days, who came home with a new ostomy, or who had worse digestive symptoms afterward. In an ACPMP webinar, Dr. Greenbaum said most patients strongly agreed that surgery was the right choice for them, including some who said the surgery had done them real harm.

What caregivers said

Dr. Greenbaum’s team then asked caregivers the same kinds of questions. Their study was published in October 2025. It included 34 caregivers of people with appendix cancer who’d had CRS/HIPEC, and the survey was anonymous. Half the caregivers had high scores on a 12-question caregiver burden scale.

The most common burden was stress from balancing caregiving with everything else in their lives. About 6 in 10 caregivers reported it. About 1 in 4 said they felt they’d lost control of their own life since their loved one got sick. Caregivers with a higher burden also had more regret about the decision and a worse quality of life.

Money stress showed up too. It was higher when the surgeon couldn’t remove all of the tumor and when the family had to travel 50 miles or more for care. In the webinar, Dr. Greenbaum said overall regret among these caregivers was very low. She also said half of them were still carrying a heavy burden.

What DECISIVE found

DECISIVE was led by Dr. Elizabeth Godfrey, a general surgery resident at Yale. It started in 2024. The survey had 117 questions and went out through ACPMP, PMP Pals and Colontown. It reached 113 people with cancer and 33 caregivers. Twelve of those caregivers answered after their loved one had died.

In DECISIVE, 14% of patients had moderate to severe regret and 14% felt surgery wasn’t worth it. Among caregivers, 21% had regrets about their decision and 35% felt it wasn’t worth it. In an ACPMP webinar, Dr. Godfrey said the higher caregiver numbers were largely driven by caregivers whose loved one had died.

Regret after the CRS/HIPEC decision in the DECISIVE study: 14% of patients and 21% of caregivers had moderate to severe regret, and 14% of patients and 35% of caregivers felt surgery wasn't worth it

That helps explain why the two caregiver studies look different at first. Dr. Greenbaum’s caregivers reported very little regret. DECISIVE included caregivers who had lost the person they cared for, and the two surveys asked different groups of people at different times.

Too little information before the CRS/HIPEC decision

DECISIVE found that people who felt they didn’t get enough information before surgery had more regret. The biggest gap was risks and side effects: 26% said they didn’t get enough information about them. Prognosis was the part of the consultation that doctors covered least well.

The biggest barrier to making the decision surprised Dr. Godfrey. It was the emotional weight of the diagnosis, along with all the work it took just to reach a doctor who could talk about cytoreduction. When people were asked what they wished they’d known, the same things came up again and again: the tubes, drains and lines after surgery, trouble sleeping, how long recovery takes, changes in digestion, survival data, and mental health.

The sources people trusted most were support groups and other survivors. Many said they had to find their own surgeon.

Dr. Godfrey said one finding changed how she thinks about these conversations. Many people told the team they wanted real numbers. In the webinar she said, “it’s easy to mistake hedging for being hopeful, and they’re not the same thing.”

A decision tool is coming

The Yale team is building a tool to help patients and families make the CRS/HIPEC decision, based on what people said in the survey. It’s organized in sections, so a person can skip the survival section if they don’t want to see it. It will be tested at Yale first, then at several centers. It will be US-only at first because of data rules, but the long-term goal is to make it free for anyone to use. The full DECISIVE paper will be free on PubMed Central soon, and I’ll write a full breakdown when it is.

What caregivers can ask before the CRS/HIPEC decision

These studies point to questions worth asking at the surgical consult:

  • what the recovery will look like for your loved one’s specific surgery
  • which tubes and drains to expect
  • how long they’ll likely be in the hospital
  • what digestive changes are common
  • who to call at night once you’re home

Ask what happens if the surgeon can’t remove all of the tumor. Ask about counseling or support for the caregiver, not only the patient. If you’re traveling far for care, ask the hospital about lodging and financial help early, before the bills and hotel costs pile up.

What these studies don’t tell us

All three are surveys of people who were connected to advocacy groups, and the caregiver groups are small. Most patients had low-grade tumors. The results aren’t broken out for goblet cell adenocarcinoma, signet ring cell carcinoma, high-grade mucinous adenocarcinoma or neuroendocrine tumors. DECISIVE also included a few people with ovarian or colon cancer. The patients and caregivers in these studies weren’t matched pairs, so a caregiver’s answers can’t be linked to a specific patient’s outcome. None of these numbers can predict how the decision will go for any one family.

Watch the researchers explain it

ACPMP recorded both teams presenting their work. Dr. Greenbaum and Dr. Kimberly Kopecky cover regret, caregiver burden and setting expectations in Expectations, Regret, and Caregiver Burden. Dr. Godfrey and Dr. Nicole Aguirre present DECISIVE in DECISIVE Study 1-Year Update.

Frequently asked questions

Do most patients regret having CRS/HIPEC?

No. In a 2024 survey of 122 people with appendix cancer, about 15% met the study’s definition of decision regret. Regret was more common after a hospital stay longer than 30 days, a new ostomy, or worse digestive symptoms.

Do caregivers regret the CRS/HIPEC decision more than patients?

In DECISIVE, more caregivers than patients had regrets (21% compared with 14%), and more felt surgery wasn’t worth it (35% compared with 14%). Dr. Godfrey said this was largely driven by caregivers whose loved one had died. In the University of New Mexico caregiver study, overall regret was very low, but half the caregivers reported a high burden.

What is caregiver burden?

It’s the physical, emotional and financial strain of caring for someone who is sick. In the University of New Mexico study, the most common burden was stress from balancing caregiving with the rest of life.

What is the DECISIVE study?

DECISIVE is a Yale study led by Dr. Elizabeth Godfrey. It surveyed patients and caregivers about deciding on cytoreductive surgery, and the team is using the results to build a decision tool. The paper was published in Annals of Surgical Oncology on September 23, 2026.

Bringing information together from patients across hospitals and countries can help researchers study questions that individual centers struggle to answer. The Appendicure Patient-Led Global Appendix Cancer Registry collects pathology, tumor mutation, and treatment information from patients around the world. It’s IRB-reviewed and free to join.

Join the Registry: United States Join the Registry: International

Already enrolled? Add new reports or correct your record here.

Appendicure is a 501(c)(3) nonprofit. If this was useful, you can support Appendicure’s work here.

Sources

Graves et al. Decision Regret in Patients with Appendiceal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2024. Read the study
Greenbaum A, et al. Decision Regret and Burden in Caregivers of Patients with Appendiceal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2025. Read the study
Godfrey EL, et al. Experiences and Decisional Outcomes After Cytoreductive Surgery for Peritoneal Surface Malignancy: The DECISIVE Study. Annals of Surgical Oncology, 2026. Read the study
ACPMP video library. Watch the webinars

0 0

Share it!

Stay informed about the latest research and patient stories.

Posted in

Leave a Reply